Halozyme Therapeutics Stock News

CP, HALO, AMX, ESTA, and GEO have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2021.

(RTTNews) - Halozyme Therapeutics, Inc. (HALO) said it expects fiscal 2022 non-GAAP earnings per share to be $2.05 to $2.20. For 2022, the company expects GAAP earnings per share of $1.90 to $2.05. For 2022, Halozyme expects GAAP net income of $270 million to $295 million and non-GAAP net income of $290 million to $315 million. For 2022,…

Do not miss out on these two fundamentally strong stocks.

Do not miss out on these two fundamentally strong stocks.

State of Michigan Retirement System grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 35,700 shares of the biopharmaceutical companys stock after purchasing an additional 2,000 shares during the quarter. State of Michigan Retirement Systems []

Halozyme Therapeutics Inc. (NASDAQ:HALO) shares, rose in value on Friday, 12/17/21, with the stock price up by 8.11% to the previous days close as strong demand from buyers drove the stock to $38.53. Actively observing the price movement in the last trading, the stock closed the session at $35.64, falling within a range of $35.46 Halozyme Therapeutics Inc. (NASDAQ: HALO) Jumps 8.11%: Is This A Sign Of Things To Come? Read More »

JMP Securities reissued their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a report issued on Friday, Price Targets.com reports. They currently have a $54.00 price objective on the biopharmaceutical companys stock. HALO has been the topic of a number of other research reports. Wells Fargo & Company dropped their target price on shares []

The stock price of Halozyme Therapeutics, Inc. (NASDAQ: HALO) increased by 8.42% in the previous trading session. This is why it happened.

JMP Securities Stick to Their Buy Rating for Halozyme Therapeutics

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared

Halozyme Therapeutics (NASDAQ:HALO) had its price target hoisted by equities research analysts at Canaccord Genuity from $27.00 to $48.00 in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage currently has a buy rating on the biopharmaceutical companys stock. Canaccord Genuitys target price would indicate a potential upside of []

The financial performance of HALO is growing at an extremely high rate, and this dynamic is expected to continue until at least 2027. The company's market prospects are undeniable, with more than 79 d

Private Advisor Group LLC grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 99.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 83,234 shares of the biopharmaceutical companys stock after purchasing an additional 41,534 shares during the quarter. Private Advisor Group LLC owned []